Edgewise Therapeutics, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
EWTX Nasdaq 2830 edgewisetx.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Edgewise Therapeutics, Inc.

What to Know About This Fund’s $50 Million Exit From Ascendis Pharma - May 14th, 2026 1:05 pm
This Fund Has a $75 Million Bet on a Hair Loss Biotech Stock Up More Than 500% Post-IPO - May 14th, 2026 12:57 pm
Why This Hedge Fund Added $29 Million to a Cancer Stock Already Up 700% - May 14th, 2026 12:51 pm
Edgewise Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference on May 20, 2026 - May 12th, 2026 6:00 am
Edgewise Therapeutics' Update for EDG-7500 Could Boost Shares, RBC Says - May 8th, 2026 11:35 am
Do Edgewise Therapeutics' (EWTX) New Stock Grants Clarify or Complicate Its Pipeline Execution Story? - May 7th, 2026 9:26 am
Edgewise Therapeutics Reports First Quarter 2026 Financial Results and Advances Clinical Programs in Muscular Dystrophy and Cardiovascular Indications - May 7th, 2026 6:00 am
How This Biotech Scored 'A Clear Win' Where Bristol Myers Failed - May 5th, 2026 2:19 pm
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules - May 4th, 2026 6:00 am
Can Myqorzo Drive Growth for Cytokinetics Amid Competition? - Apr 17th, 2026 11:37 am
Edgewise Therapeutics, Inc. (EWTX) PT Increased to $45 at JPMorgan Amid Optimism on EDG-7500 Pipeline - Mar 30th, 2026 5:40 am
Why Edgewise Therapeutics Stock Topped the Market on Tuesday - Mar 17th, 2026 4:51 pm
Assessing Edgewise Therapeutics (EWTX) Valuation After Encouraging Long Term MESA Study Results - Mar 16th, 2026 11:09 am
Why Edgewise Therapeutics (EWTX) Is Up 6.4% After Long-Term Sevasemten Becker Data - And What's Next - Mar 16th, 2026 12:05 am
Edgewise Therapeutics Talks Phase III Becker Readout, EDG-7500 HCM Data Due in Q2 at Conference - Mar 15th, 2026 9:02 pm
This Investor Sold $5 Million of a Biotech Stock Up 118% in a Year, but Here's Why It Still Seems Bullish on Shares - Mar 15th, 2026 4:27 pm
This Investor Built a $56 Million Position in RAPT Last Quarter. It Was Just Acquired for $58 Per Share - Mar 15th, 2026 4:20 pm
Edgewise Announces Positive Long-Term Sevasemten Data Demonstrating Sustained Functional Stabilization in Becker Muscular Dystrophy Through 3.5 Years of Follow-Up - Mar 10th, 2026 5:00 am
Edgewise Therapeutics to Present at the Leerink Global Healthcare Conference on March 11, 2026 - Mar 4th, 2026 6:00 am
Edgewise Therapeutics to Present on Sevasemten for the Treatment of Becker Muscular Dystrophy at the 2026 MDA Clinical and Scientific Conference - Mar 3rd, 2026 6:00 am